Business
Preparing SCIB2 for clinical study in lung cancer
Preparing SCIB2 for clinical study in lung cancer.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0748M Scancell Holdings Plc 10 October 2016 \n\n10 October 2016\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell preparing SCIB2 for clinical study in lung cancer\n \n· SCIB2 will be developed for the treatment of non-small cell lung cancer in combination with a checkpoint inhibitor\n· Latest SCIB2 data published in peer-reviewed journal OncoImmunology confirms potent anti-tumour activity was further enhanced by checkpoint blockade\n· Extension of clinical application from melanoma to lung cancer highlights potential of ImmunoBody® platform technology to target broad range of cancers \n \n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, today announces its intention to develop its SCIB2 ImmunoBody® for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor. Scancell's Board approved the decision based on the outstanding results from the SCIB1 melanoma clinical trial which extended several years beyond the original completion date due to the unexpectedly long survival times. Planning for Phase I/II clinical trials in NSCLC is currently underway. \n \nThe latest data on SCIB2 has recently been published in OncoImmunology1, a highly regarded journal at the frontier between oncology and immunology. The results confirmed that SCIB2, an ImmunoBody® encoding NY-ESO-1 epitopes, induced potent anti-tumour immunity which was further enhanced by checkpoint blockade.\n \nProf Lindy Durrant, Chief Scientific Officer of Scancell, said: \"Our clinical experience with the first ImmunoBody®, SCIB1, in the melanoma setting will greatly facilitate planning and execution of our planned lung cancer clinical trials with SCIB2. We believe that success with this clinical programme will highlight that ImmunoBody® has the potential to be applicable to cancers with very different characteristics and underlying genetics.\" \n \nDr Richard Goodfellow, Chief Executive Officer of Scancell, said: \"It is recognised that the successful exploitation of novel therapeutic mechanisms, such as that underlying our ImmunoBody® platform, will be critical to further improvi...